SignalDailyGlobal signals. Global context.

Market Incident

Public · Developing

AI compiled from Infoway · 4 analyzed stories

Earnings Snapshot: AbbVie beats Q3 EPS and revenue views, raises full-year earnings guidance

AbbVie reported third-quarter earnings that beat analyst views for both earnings per share and revenue, and the company raised its guidance for full-year earnings, according to the supplied headline.

Published:

Updated:

What happened

AbbVie reported third-quarter revenue of $17.4 billion, up about 10% from a year earlier, beating expectations. Skyrizi and Rinvoq sales grew while Humira sales fell. Adjusted earnings per share were $3.82, beating the consensus. The company raised its full-year earnings guidance and announced a dividend increase.

Global impact / market context

The results show the company is selling more of its newer medicines as an older one shrinks, and it expects to earn more this year than previously thought. It is also paying shareholders a slightly bigger dividend.

What to watch

  1. Whether Skyrizi and Rinvoq keep growing fast enough to offset the Humira decline, since Humira sales fell 31% — this matters because the company's revenue now depends more on those two drugs.
  2. Whether the raised full-year earnings guidance holds up in later quarters, because the higher outlook is the company's own forecast and could change.
  3. What happens to the dividend increase and overall costs, because a bigger payout uses cash that could otherwise support the business.

Affected assets

  • ABBV

Evidence